Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms.
Published on Oct 23, 2015
This clip features Professor Meredith Rosenthal, Dr. Aaron Kesselheim and Dr. Steven Pearson, who spoke during Drug Pricing: Public Health Implications on Friday, October 23, 2015. The event was presented in collaboration with Reuters and in association with Harvard Health Publications.
(This version of the March 12 story corrects year in paragraph 7, removes reference to Spectrum Rare Earths in paragraph 19)
Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded
A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.
Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.
NEW YORK Martin Shkreli, the former drug company executive who made headlines by jacking up the price of a lifesaving drug before he was found guilty of defrauding investors, was sentenced to 7 years and a $75,000 fine on Friday. | Video
U.S. health insurer Cigna Corp struck a $52-billion deal to buy pharmacy benefits manager (PBM) Express Scripts Holding Co on Thursday, looking for new ways to hold onto their profits as the industry faces greater scrutiny for rising healthcare costs. | Video
WASHINGTON U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for "Kabuki drug-pricing constructs" that profit the industry at the expense of consumers.
Amazon.com Inc said on Wednesday it was expanding its discounted Prime membership offer to Medicaid members, the U.S. government's health insurance program for the poor.
Europe's medicines regulator recommended the immediate suspension and recall of Biogen Inc and AbbVie Inc's multiple sclerosis drug Zinbryta, following 12 reports of inflammation of the brain, three of which cases were fatal.
Reuters Collaborations with The Forum at Harvard T.H. Chan School of Public Health
NEW ORLEANS The number of Americans drinking a daily cup of coffee is at the highest level since 2012, with demand continuing to get a boost from at-home consumption and gourmet drinks, an industry study showed on Saturday.
(Reuters Health) - A dash of cumin or dill might help convince high school students to load up their plate with vegetables during lunchtime in the cafeteria, a small study suggests.
LONDON, March 16 A huge and deadly outbreak of listeria in South Africa could alter the country's approach to food-borne disease and prompt improvements in food safety standards, a leading health official said on Friday.
(Reuters Health) - People who have slightly elevated blood sugar that’s not high enough for a diabetes diagnosis may still have a higher risk of heart and kidney disease than individuals with normal blood sugar, a U.S. study suggests.
NEW YORK In 2014, as Jonathan Rubin and Ian Laird considered investing in the booming U.S. cannabis industry, they hit a problem: How to value pot start-ups with little verified data on the price of the weed itself?